ClinicalTrials.gg
RecruitingNCT07347366Updated Jan 16, 2026

Electromagnetic High-Frequency Chest Wall Oscillation on Pulmonary Mucus Clearance in Patients With Impaired Self-Expectoration

An interventional study of CAREWAY and EM HFLS CWSE(Nine-Motor) in Sputum, sponsored by Pusan National University Yangsan Hospital. Recruiting at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Pusan National University Yangsan Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Sep 2025, registered Dec 2025).
  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This exploratory study aims to evaluate the efficacy and safety of an electromagnetic high-frequency, low-strain chest wall oscillation device for enhancing pulm

02

Conditions studied

  • Sputum

Keywords

  • sputum clearance
  • respiratory symptoms
  • Pulmonary Mucus Clearance
  • Electromagnetic High-Frequency Chest Wall Oscillation
03

In context

Signs and Symptoms, Respiratory

64 studies on the registry are indexed under Signs and Symptoms, Respiratory; 9 are open to participants now.

This study's planned enrollment of 45 is below the median of 120 across 43 interventional studies indexed under Signs and Symptoms, Respiratory.

Browse Signs and Symptoms, Respiratory studies →

Lead sponsor

Pusan National University Yangsan Hospital is the lead sponsor of 108 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized patients who require sputum clearance.
  • Patients who present with fever or respiratory symptoms (cough, sputum) and, after confirmation of findings on imaging studies, are judged by the clinician to require sputum clearance.
  • Adult patients (≥ 18 years) who have signed the form, or patients for whom consent has been obtained from a legally authorized representative

Exclusion criteria

Exclusion Criteria:

  • Patients with severe pneumonia requiring intensive care unit (ICU) treatment.
  • Patients with major pulmonary diseases other than pneumonia, such as active tuberculosis or lung cancer.
  • Patients with severe respiratory failure (PaO₂/FiO₂ ≤ 200 mmHg).
  • Patients with hemodynamically unstable cardiovascular disease (myocardial infarction within the past 3 months, or heart failure of class 3 or higher).
  • Patients hospitalized for head and neck trauma whose surgical site has not yet healed.
  • Patients with serious cardiac arrhythmias or hemodynamic instability.
  • Patients who have had pneumothorax or massive hemoptysis within the past 6 months, or who currently have hemoptysis.
  • Patients who have undergone spinal surgery within the past 6 months or who have acute spinal injury.
  • Patients with osteoporosis.
  • Patients with bronchopleural fistula.
  • Pregnant or breastfeeding women.
  • Patients diagnosed with cervical disc disease.
  • Individuals who have participated in clinical studies two or more times in the same year, or who have participated in another clinical study within the past 6 months (however, patients enrolled in chronic lung disease cohort studies such as asthma or are allowed).
  • Individuals who, in the judgment of the principal investigator or sub-investigator, have findings that make them unsuitable for participation in this study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
45 participants (estimated)

Study arms

  • Active comparator
    Control Group

    A high-frequency chest wall oscillation device in the form of a vest (Todaki) is used in patients who require clearance of mucus retained in the lungs, providing high-frequency chest wall vibrations to dislodge sputum adherent to the bronchial walls and facilitate removal of secretions.

    Device: CAREWAY

  • Experimental
    Nine-Motor Device Group

    Description:This bed-type medical device delivers vibrational energy across the chest wall for patients with respiratory conditions. aiding in the clearance of accumulated sputum in the airways and lungs. It incorporates nine electromagnetic high-frequency, low-strain vibration motors to produce distributed vibrational energy, which is applied via the chest wall oscillation plate to multiple lung regions, enhancing comprehensive sputum clearance through multi-point oscillation

    Device: EM HFLS CWSE(Nine-Motor)

  • Experimental
    Single-Motor Device Intervention

    Description: This bed-type medical device applies vibrational energy to the chest wall of patients with respiratory diseases to facilitate sputum clearance from the airways and lungs. The device employs a single electromagnetic high-frequency, low-strain vibration motor that generates vibrational energy, which transmits through the chest wall oscillation plate directly to the patient's chest, promoting effective mucus mobilization via targeted oscillations.

    Device: EM HFLS CWSE(Single-motor)

Interventions

  • DeviceCAREWAY

    CAREWAY , A high-frequency chest wall oscillation device in the form of a vest (Todaki) is used in patients who require clearance of mucus retained in the lungs, providing high-frequency chest wall vibrations to dislodge sputum adherent to the bronchial walls and facilitate removal of secretions.

  • DeviceEM HFLS CWSE(Nine-Motor)

    This bed-type medical device delivers vibrational energy across the chest wall for patients with respiratory conditions aiding in the clearance of accumulated sputum in the airways and lungs. It incorporates nine electromagnetic high-frequency, low-strain vibration motors to produce distributed vibrational energy, which is applied via the chest wall oscillation plate to multiple lung regions, enhancing comprehensive sputum clearance through multi-point oscillation

  • DeviceEM HFLS CWSE(Single-motor)

    This bed-type medical device applies vibrational energy to the chest wall of patients with respiratory diseases , to facilitate sputum clearance from the airways and lungs. The device employs a single electromagnetic high-frequency, low-strain vibration motor that generates vibrational energy, which transmits through the chest wall oscillation plate directly to the patient's chest, promoting effective mucus mobilization via targeted oscillations.

06

What researchers measure

Primary outcomes

  1. BCSS, Breathlessness, Cough, and Sputum Scale

    The Breathlessness, Cough, and Sputum Scale (BCSS) is a patient-reported outcome measure assessing the severity of breathlessness, cough, and sputum. Each symptom is rated by the patient on a numeric scale from 0 (no symptoms) to 4 (severe symptoms). Individual symptom scores and the total score, calculated as the sum of the three items (range 0-12), are used for analysis, with higher scores indicating more severe symptoms.

    Time frame: Change rate in Breathlessness, Cough, and Sputum Scale (BCSS) scores at 1 week compared with baseline.

Secondary outcomes

  1. mMRC (modified Medical Research Council Dyspnea Scale)

    The modified Medical Research Council (mMRC) Dyspnea Scale is a patient-reported measure assessing the degree of breathlessness during daily activities. Dyspnea severity is rated on a 5-point ordinal scale ranging from 0 (breathlessness only with strenuous exercise) to 4 (too breathless to leave the house or breathless when dressing or undressing). Higher scores indicate more severe dyspnea.

    Time frame: Change rate in modified Medical Research Council (mMRC) dyspnea scores at 1 week compared with baseline for patient symptom assessment.

  2. St. George's Respiratory Questionnaire (SGRQ)

    The St. George's Respiratory Questionnaire (SGRQ) is a validated patient-reported outcome measure assessing health-related quality of life in patients with respiratory disease. It consists of three domains: Symptoms, Activity, and Impacts. Domain scores and the total score range from 0 to 100, with higher scores indicating worse health status and greater impairment of respiratory-related quality of life.

    Time frame: Change rate in St. George's Respiratory Questionnaire (SGRQ) scores at 1 week compared with baseline.

  3. Visual Analog Scale for Dyspnea (VASD)

    It is a subjective assessment scale in which patients rate their perceived "difficulty in breathing" from 0 (none) to 10 (worst), and it is used to objectively assess changes in symptoms and evaluate treatment effects in patients with respiratory or cardiac diseases

    Time frame: Scores at 1 week compared with baseline.

  4. VAS (Visual Analogue Scale) - Cough

    The severity of cough (VAS) is assessed using a Visual Analogue Scale, a subjective method in which patients rate the severity of their cough by marking their symptoms on a straight line from 0 (no cough at all) to 10 (the worst imaginable), which is then recorded as a score.

    Time frame: Scores at 1 week compared with baseline.

  5. Cough And Sputum Assessment Questionnaire (CASA-Q)

    Cough and sputum were assessed using the Cough and Sputum Assessment Questionnaire (CASA-Q), which evaluates symptom severity and impact across four domains. Domain scores range from 0 to 100, with higher scores indicating less severe symptoms and lower disease impact.

    Time frame: Scores at 1 week compared with baseline.

  6. Oxygen saturation (SpO2)

    Oxygen saturation measured by pulse oximetry, defined as the percentage of hemoglobin saturated with oxygen in arterial blood. Values are expressed as a percentage (%), with higher values indicating better oxygenation status.

    Time frame: Data at 1 week compared with baseline.

  7. Forced Vital Capacity (FVC)

    Forced vital capacity measured using pulmonary function testing, defined as the maximum volume of air forcibly exhaled after full inspiration. Values are recorded in liters (L).

    Time frame: Data at 1 week compared with baseline.

  8. Forced Expiratory Volume in 1 Second (FEV1)

    Forced expiratory volume in one second measured using pulmonary function testing, defined as the volume of air forcibly exhaled in the first second of a forced expiration. Values are recorded in liters (L).

    Time frame: Data at 1 week compared with baseline.

  9. FEV1/FVC Ratio

    The ratio of forced expiratory volume in one second to forced vital capacity measured using pulmonary function testing. Values are expressed as a percentage (%).

    Time frame: Data at 1 week compared with baseline.

  10. Forced Expiratory Flow 25-75% (FEF 25-75)

    Forced expiratory flow between 25% and 75% of forced vital capacity measured using pulmonary function testing, reflecting airflow in the mid-portion of forced expiration. Values are recorded in liters per second (L/s).

    Time frame: Data at 1 week compared with baseline.

  11. Peak Expiratory Flow (PEF)

    Peak expiratory flow measured using pulmonary function testing, defined as the maximum flow achieved during a forced expiration. Values are recorded in liters per minute (L/min).

    Time frame: Data at 1 week compared with baseline.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Oct 2026, 13 months after the start.

Of 18 interventional studies with no phase under Signs and Symptoms, Respiratory, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 13 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2025
First posted
Jan 16, 2026
StartActual
Sep 23, 2025
Primary completionEst.
Oct 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07347366
Responsible party
Yong-il Shin (Professor, Pusan National University Yangsan Hospital) — Principal investigator
First posted
Jan 16, 2026
Start date
Sep 23, 2025
Primary completion
Oct 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 16, 2026

Study contacts

Jisoo Baik, Doctoral
Contact
zisoo@pusan.ac.kr
82+055-360-4159

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion